Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Hepatic Function during Repeated TACE Procedures and Prognosis after Introducing Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: Multicenter Analysis
Atsushi Hiraoka, Takashi Kumada, Masatoshi Kudo, et al.
Digestive Diseases (2017) Vol. 35, Iss. 6, pp. 602-610
Closed Access | Times Cited: 125

Showing 1-25 of 125 citing articles:

Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial
Masatoshi Kudo, Kazuomi Ueshima, Masafumi Ikeda, et al.
Gut (2019) Vol. 69, Iss. 8, pp. 1492-1501
Open Access | Times Cited: 568
Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update
Masatoshi Kudo, Yusuke Kawamura, Kiyoshi Hasegawa, et al.
Liver Cancer (2021) Vol. 10, Iss. 3, pp. 181-223
Open Access | Times Cited: 493
Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child–Pugh A Liver Function: A Proof-Of-Concept Study
Masatoshi Kudo, Kazuomi Ueshima, Stephan Chan, et al.
Cancers (2019) Vol. 11, Iss. 8, pp. 1084-1084
Open Access | Times Cited: 253
A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements
Masatoshi Kudo, Kwang–Hyub Han, Sheng-Long Ye, et al.
Liver Cancer (2020) Vol. 9, Iss. 3, pp. 245-260
Open Access | Times Cited: 240
Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions—Multicenter analysis
Atsushi Hiraoka, Takashi Kumada, Masanori Atsukawa, et al.
Cancer Medicine (2019) Vol. 8, Iss. 8, pp. 3719-3728
Open Access | Times Cited: 153
EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma
Bruno Sangro, Lorenza Rimassa, Maxime Ronot, et al.
Journal of Hepatology (2024)
Closed Access | Times Cited: 30
Impact of Baseline ALBI Grade on the Outcomes of Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Study
Kazuomi Ueshima, Naoshi Nishida, Satoru Hagiwara, et al.
Cancers (2019) Vol. 11, Iss. 7, pp. 952-952
Open Access | Times Cited: 135
A New Treatment Option for Intermediate-Stage Hepatocellular Carcinoma with High Tumor Burden: Initial Lenvatinib Therapy with Subsequent Selective TACE
Masatoshi Kudo
Liver Cancer (2019) Vol. 8, Iss. 5, pp. 299-311
Open Access | Times Cited: 125
Newly Proposed ALBI Grade and ALBI-T Score as Tools for Assessment of Hepatic Function and Prognosis in Hepatocellular Carcinoma Patients
Atsushi Hiraoka, Takashi Kumada, Kojiro Michitaka, et al.
Liver Cancer (2018) Vol. 8, Iss. 5, pp. 312-325
Open Access | Times Cited: 119
Clinical-Radiomic Analysis for Pretreatment Prediction of Objective Response to First Transarterial Chemoembolization in Hepatocellular Carcinoma
Mingyu Chen, Jiasheng Cao, Jiahao Hu, et al.
Liver Cancer (2021) Vol. 10, Iss. 1, pp. 38-51
Open Access | Times Cited: 89
Therapeutic potential of lenvatinib for unresectable hepatocellular carcinoma in clinical practice: Multicenter analysis
Atsushi Hiraoka, Takashi Kumada, Kazuya Kariyama, et al.
Hepatology Research (2018) Vol. 49, Iss. 1, pp. 111-117
Open Access | Times Cited: 87
Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma
Atsushi Hiraoka, Takashi Kumada, Masanori Atsukawa, et al.
Oncology (2019) Vol. 97, Iss. 5, pp. 277-285
Closed Access | Times Cited: 80
Which is the best combination of TACE and Sorafenib for advanced hepatocellular carcinoma treatment? A systematic review and network meta-analysis
Fan Feng, Qiyu Jiang, Hui Jia, et al.
Pharmacological Research (2018) Vol. 135, pp. 89-101
Closed Access | Times Cited: 60
Lenvatinib-Transarterial Chemoembolization Sequential Therapy as an Effective Treatment at Progression during Lenvatinib Therapy for Advanced Hepatocellular Carcinoma
Yusuke Kawamura, Masahiro Kobayashi, Junichi Shindoh, et al.
Liver Cancer (2020) Vol. 9, Iss. 6, pp. 756-770
Open Access | Times Cited: 59
Lenvatinib prolongs the progression‑free survival time of patients with intermediate‑stage hepatocellular carcinoma refractory to transarterial chemoembolization: A multicenter cohort study using data mining analysis
Shigeo Shimose, Takumi Kawaguchi, Masatoshi Tanaka, et al.
Oncology Letters (2020) Vol. 20, Iss. 3, pp. 2257-2265
Open Access | Times Cited: 54
Switching to systemic therapy after locoregional treatment failure: Definition and best timing
Sadahisa Ogasawara, Yoshihiko Ooka, Keisuke Koroki, et al.
Clinical and Molecular Hepatology (2020) Vol. 26, Iss. 2, pp. 155-162
Open Access | Times Cited: 53
EZ-ALBI Score for Predicting Hepatocellular Carcinoma Prognosis
Kazuya Kariyama, Kazuhiro Nouso, Atsushi Hiraoka, et al.
Liver Cancer (2020) Vol. 9, Iss. 6, pp. 734-743
Open Access | Times Cited: 51
Transarterial Chemoembolization (TACE) Plus Sorafenib Compared to TACE Alone in Transplant Recipients with Hepatocellular Carcinoma: An Institution Experience
Maen Abdelrahim, David W. Victor, Abdullah Esmail, et al.
Cancers (2022) Vol. 14, Iss. 3, pp. 650-650
Open Access | Times Cited: 29
Clinical application of Albumin-Bilirubin (ALBI) score: The current status
Min Deng, Sally W. Y. Ng, ST Cheung, et al.
The Surgeon (2019) Vol. 18, Iss. 3, pp. 178-186
Closed Access | Times Cited: 50
Clinical characteristics and outcomes of candidates for second‐line therapy, including regorafenib and ramucirumab, for advanced hepatocellular carcinoma after sorafenib treatment
Teiji Kuzuya, Masatoshi Ishigami, Takanori Ito, et al.
Hepatology Research (2019) Vol. 49, Iss. 9, pp. 1054-1065
Closed Access | Times Cited: 45
Early Relative Change in Hepatic Function with Lenvatinib for Unresectable Hepatocellular Carcinoma
Atsushi Hiraoka, Takashi Kumada, Masanori Atsukawa, et al.
Oncology (2019) Vol. 97, Iss. 6, pp. 334-340
Closed Access | Times Cited: 44
Ultraselective conventional transarterial chemoembolization: When and how?
Shiro Miyayama
Clinical and Molecular Hepatology (2019) Vol. 25, Iss. 4, pp. 344-353
Open Access | Times Cited: 43
Post-Progression Treatment Eligibility of Unresectable Hepatocellular Carcinoma Patients Treated with Lenvatinib
Atsushi Hiraoka, Takashi Kumada, Shinya Fukunishi, et al.
Liver Cancer (2019) Vol. 9, Iss. 1, pp. 73-83
Open Access | Times Cited: 43
Pretreatment Heterogeneous Enhancement Pattern of Hepatocellular Carcinoma May Be a Useful New Predictor of Early Response to Lenvatinib and Overall Prognosis
Yusuke Kawamura, Masahiro Kobayashi, Junichi Shindoh, et al.
Liver Cancer (2020) Vol. 9, Iss. 3, pp. 275-292
Open Access | Times Cited: 40
TACE Combined with Lenvatinib and Camrelizumab for Unresectable Multiple Nodular and Large Hepatocellular Carcinoma (>5 cm)
Zhanwang Xiang, Guohong Li, Luwen Mu, et al.
Technology in Cancer Research & Treatment (2023) Vol. 22
Open Access | Times Cited: 14
Page 1 - Next Page

Scroll to top